Identifying genetic variants linked to hypertension in breast cancer patients treated with bevacizumab
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
This study is trying to find out if certain genetic traits make breast cancer patients more likely to develop high blood pressure while being treated with a drug called bevacizumab.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 354 (estimated) |
| Sex | All |
| Sponsor | National Cancer Institute (NCI) NIH |
| Drugs / interventions | bevacizumab |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT02610413 on ClinicalTrials.gov |
What this trial studies
This research focuses on using whole exome sequencing to analyze germline DNA samples from patients with breast cancer who have experienced hypertension while receiving bevacizumab. The primary goal is to identify rare genetic variants that may contribute to the risk of hypertension in these patients. By studying previously collected DNA samples, researchers aim to uncover biomarkers that could help in understanding the genetic factors associated with hypertension in this specific patient population.
Who should consider this trial
Good fit: Ideal candidates include European American patients who have either developed severe hypertension during bevacizumab treatment or those who did not experience hypertension after completing the treatment.
Not a fit: Patients who are not of European American descent or those who did not receive bevacizumab for breast cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of hypertension in breast cancer patients undergoing treatment with bevacizumab.
How similar studies have performed: While this approach is innovative, it builds on existing knowledge of genetic factors in hypertension, and similar studies have shown promise in identifying genetic variants related to other conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * European American patients with deoxyribonucleic acid (DNA) available and designated case or control * Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab * Patients who did not develop hypertension following a full course of treatment with bevacizumab
Where this trial is running
Boston, Massachusetts
- Eastern Cooperative Oncology Group — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Bryan P Schneider — Eastern Cooperative Oncology Group
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.